Skip to main content
. Author manuscript; available in PMC: 2013 Nov 25.
Published in final edited form as: Mol Endocrinol. 2007 May 15;21(8):10.1210/me.2006-0467. doi: 10.1210/me.2006-0467

Figure 3. Androgen and antagonists alter histone H3 acetylation at the PSA promoter.

Figure 3

A) Histone H3 acetylation at the PSA promoter. Cross-linked chromatin was extracted from cells cultured under androgen-deprivation conditions and then treated with 10 nM DHT (D), or DHT plus 25 μM resveratrol (D+RES), or vehicle (S) for 4 hr. Anti-Histone H3 antibody (AcH3) or an irrelevant antibody (anti-RAG) were used for immunoprecipitation. The ethidium-stained PCR products of the ChIP assay are shown. B) Quantitative PCR results from the same ChIP assays, analyzing both the PSA promoter and enhancer. C) Quantitative PCR analysis of ChIP assays for acetylated histone H3 at the PSA promoter or enhancer in the presence of DHT in control-transfected LNCaP cells (Ctrl) and in LNCaP cell lines in which SIRT1 expression levels had been knocked down by stable expression of siRNA (RNAi). Asterisks (*) indicates significant differences between two groups (p<0.05).